Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves
Abstract
Sulfonamides (S) are long-established antibacterial drugs frequently combined with trimethoprim (TMP) for synergistic effects against bacterial infections in food-producing animals, such as bovine respiratory diseases. In veterinary medicine, the current administered TMP:S ratio of 1:5 is based on the human dosing regimen that is limited to the single combination of TMP and sulfamethoxazole (SMX), targeting an in vivo concentration ratio of 1:19, considered an appropriate synergistic ratio against human pathogens. However, several sulfonamides are used in veterinary practice each leading to distinct pharmacokinetic profiles and thereby questioning the relevance of extrapolating this dose ratio. This study characterized the parenteral pharmacokinetics (PK) of three TMP/S combinations in calves. Data were used to develop population PK models and to simulate in vivo free-concentration ratios at the herd level. A 2-compartment model fitted best sulfadiazine (SDZ), SMX and TMP data while sulfadimethoxine (SDMX) needed a third compartment. SDMX had the lowest clearance (0.02 L/h/kg) while SMX and SDZ showed similar values (0.13 and 0.12 L/h/kg, respectively). TMP exhibited the highest clearance (1.41 L/h/kg). Elimination half-lives were 19.67 h for SDMX, 3.54 h for SDZ, 2.21 h for SMX and 1.39 h for TMP. Monte Carlo simulations indicated that only 0.2% (TMP/SDZ), 11.6% (TMP/SMX) and 21% (TMP/SDMX) of simulated calves (n = 50,000) reached ratios between 1:10 – 1:50 at marketed doses. These results provide a first step toward optimizing the antimicrobial activity of these antibacterial, highlighting the need for further PD and PK/PD investigations.
Related
- Prior-informed population pharmacokinetic-pharmacodynamic modeling of dexamethasone in horses
- Population pharmacokinetic model–based determination of enrofloxacin susceptibility breakpoints and dosing regimens for Salmonella in chickens
- Trimethoprim suppress phage activity and reduces toxin production in a clinical STEC strain, even in the presence of DNA-damaging antibiotics
- Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius
- Unraveling Trimethoprim-Sulfonamide synergy against Escherichia coli through semi-mechanistic PK/PD modeling
BibTeX
@article{boulanger2026population,
title = {{Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves}},
author = {Marine Boulanger and Béatrice B Roques and Marlène Z Lacroix and Lucie Claustre and Mathias Devreese and Siegrid de Baere and Alexis Viel and Aude A Ferran},
journal = {Veterinary Journal},
year = {2026},
month = aug,
doi = {10.1016/j.tvjl.2026.106842},
url = {https://anses.hal.science/anses-05799897v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves
AU - Marine Boulanger
AU - Béatrice B Roques
AU - Marlène Z Lacroix
AU - Lucie Claustre
AU - Mathias Devreese
AU - Siegrid de Baere
AU - Alexis Viel
AU - Aude A Ferran
PY - 2026
DA - 2026/08/20
JO - Veterinary Journal
DO - 10.1016/j.tvjl.2026.106842
UR - https://anses.hal.science/anses-05799897v1
AB - Sulfonamides (S) are long-established antibacterial drugs frequently combined with trimethoprim (TMP) for synergistic effects against bacterial infections in food-producing animals, such as bovine respiratory diseases. In veterinary medicine, the current administered TMP:S ratio of 1:5 is based on the human dosing regimen that is limited to the single combination of TMP and sulfamethoxazole (SMX), targeting an in vivo concentration ratio of 1:19, considered an appropriate synergistic ratio against human pathogens. However, several sulfonamides are used in veterinary practice each leading to distinct pharmacokinetic profiles and thereby questioning the relevance of extrapolating this dose ratio. This study characterized the parenteral pharmacokinetics (PK) of three TMP/S combinations in calves. Data were used to develop population PK models and to simulate in vivo free-concentration ratios at the herd level. A 2-compartment model fitted best sulfadiazine (SDZ), SMX and TMP data while sulfadimethoxine (SDMX) needed a third compartment. SDMX had the lowest clearance (0.02 L/h/kg) while SMX and SDZ showed similar values (0.13 and 0.12 L/h/kg, respectively). TMP exhibited the highest clearance (1.41 L/h/kg). Elimination half-lives were 19.67 h for SDMX, 3.54 h for SDZ, 2.21 h for SMX and 1.39 h for TMP. Monte Carlo simulations indicated that only 0.2% (TMP/SDZ), 11.6% (TMP/SMX) and 21% (TMP/SDMX) of simulated calves (n = 50,000) reached ratios between 1:10 – 1:50 at marketed doses. These results provide a first step toward optimizing the antimicrobial activity of these antibacterial, highlighting the need for further PD and PK/PD investigations.
SN - 1090-0233
SN - 1532-2971
ER -